Page last updated: 2024-11-02

perphenazine and Chemical Dependence

perphenazine has been researched along with Chemical Dependence in 9 studies

Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.

Research Excerpts

ExcerptRelevanceReference
"Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment."5.13The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008)
"Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone."2.58Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. ( Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T, 2018)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19903 (33.33)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Temmingh, HS1
Williams, T1
Siegfried, N1
Stein, DJ1
Mohamed, S1
Rosenheck, RA1
Lin, H1
Swartz, M1
McEvoy, J1
Stroup, S1
FRANKAU, L1
Swartz, MS1
Wagner, HR1
Swanson, JW1
Stroup, TS1
McEvoy, JP1
Reimherr, F1
Miller, DD1
McGee, M1
Khan, A1
Canive, JM1
Davis, SM1
Hsiao, JK1
Lieberman, JA1
Ghoreishi, A1
Goodhue, A1
Bartel, RL1
Smith, NB1
Bowers, MB1
Mazure, CM1
Nelson, JC1
Jatlow, PI1
de la Garza, R1
Johanson, CE1
Dorfman, W1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715]Phase 423 participants (Actual)Interventional2004-03-31Completed
Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923]Phase 495 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Symptoms

The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks

InterventionUnits on a scale (Mean)
QUET65.5

Mean Number of Drinking Days Per Week

Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks

InterventionDrinking Days per Week (Mean)
QUET2.7

Average Over Time of Frequency of Drinking Days (Used to Evaluate Treatment Efficacy)

Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventiondrinking days per week (Number)
Risperidone Long Acting Injectable (LAI)2.84
Oral Risperidone Aka Risperdal3.46

Average Over Time of Global Functioning (Used to Evaluate Treatment Efficacy)

A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionordinal severity of impairment (Number)
Risperidone Long Acting Injectable (LAI)50.8
Oral Risperidone Aka Risperdal49.9

Average Over Time of Positive and Negative Symptoms (Used to Evaluate Treatment Efficacy)

A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionordinal severity of symptoms (Number)
Risperidone Long Acting Injectable (LAI)78.2
Oral Risperidone Aka Risperdal75.5

Average Over Time of Severity of Illness and Global Improvement (Used to Evaluate Treatment Efficacy)

A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionordinal unit of severity (Number)
Risperidone Long Acting Injectable (LAI)4.02
Oral Risperidone Aka Risperal3.96

Change Over Time in Frequency of Heavy Drinking Days (Used to Evaluate Treatment Efficacy)

Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionheavy drinking days per week (Number)
Risperidone Long Acting Injectable (LAI)-.11
Oral Risperidone Aka Risperal.68

Number of Participants With Medication Adherence

Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Risperidone Long Acting Injectable (LAI)43
Oral Risperidone Aka Risperdal28

Reviews

1 review available for perphenazine and Chemical Dependence

ArticleYear
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
    The Cochrane database of systematic reviews, 2018, Jan-22, Volume: 1

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disor

2018

Trials

2 trials available for perphenazine and Chemical Dependence

ArticleYear
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
    The Journal of nervous and mental disease, 2015, Volume: 203, Issue:7

    Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi

2015
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
    Schizophrenia research, 2008, Volume: 100, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub

2008

Other Studies

6 other studies available for perphenazine and Chemical Dependence

ArticleYear
TREATMENT IN ENGLAND OF CANADIAN PATIENTS ADDICTED TO NARCOTIC DRUGS.
    Canadian Medical Association journal, 1964, Feb-08, Volume: 90

    Topics: Antisocial Personality Disorder; Ascorbic Acid; Canada; England; Folic Acid; Heroin; Humans; London;

1964
A somatic type delusional disorder secondary to peripheral neuropathy: a case report.
    Psychiatria Danubina, 2008, Volume: 20, Issue:1

    Topics: Adult; Amitriptyline; Biperiden; Brachial Plexus; Delusions; Drug Overdose; Drug Therapy, Combinatio

2008
Exacerbation of psychosis by phenylpropanolamine.
    The American journal of psychiatry, 2000, Volume: 157, Issue:6

    Topics: Adult; Female; Hallucinations; Humans; Methamphetamine; Nasal Decongestants; Paranoid Disorders; Par

2000
Psychotogenic drug use and neuroleptic response.
    Schizophrenia bulletin, 1990, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan

1990
Psychotogenic drug use and neuroleptic response.
    Schizophrenia bulletin, 1990, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan

1990
Psychotogenic drug use and neuroleptic response.
    Schizophrenia bulletin, 1990, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan

1990
Psychotogenic drug use and neuroleptic response.
    Schizophrenia bulletin, 1990, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan

1990
The effects of food deprivation on the self-administration of psychoactive drugs.
    Drug and alcohol dependence, 1987, Volume: 19, Issue:1

    Topics: Animals; Cocaine; Dextroamphetamine; Diazepam; Food Deprivation; Macaca mulatta; Male; Nicotine; Per

1987
Combined use of an anti-depressant with tranquilizer in the management of depression.
    Diseases of the nervous system, 1966, Volume: 7 Suppl, Issue:7

    Topics: Amitriptyline; Anxiety; Bipolar Disorder; Depression; Drug Synergism; Electroconvulsive Therapy; Hum

1966